Fluorotechnics expands global capability via acquisition of ETC Elektrophorese-Technik

14-Nov-2007

Fluorotechnics announced the acquisition of ETC Elektrophorese-Technik. Under the terms of the acquisition, Fluorotechnics will acquire all issued shares in ETC Elektrophorese-Technik in exchange for Fluorotechnics shares. ETC Elektrophorese-Technik develops and manufactures high-end electrophoresis consumables and equipment used for diagnostics, quality control and species identification.

Fluorotechnics CEO, Duncan Veal, states, "We are very excited by the synergies that the combination of the two companies will bring. This acquisition will allow us to cross-sell products to existing customers and to address new markets utilizing our joint expertise. Our ever-expanding sales and marketing team and enormous potential for our product offering means that we are well positioned for strong growth."

The integrated company will retain its manufacturing bases in Sydney, Australia and Kirchentellinsfurt, Germany. Duncan Veal will continue as CEO, Hanspeter Schickle, CEO of ETC, will become head of product development in electrophoresis, and Günter Theßeling, a recent appointment from GE Healthcare, will spearhead the sales and marketing drive.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.